Pfizer Inc (PFE)

$25.04 +0.64 (2.62%)
Market Cap 141.46B
Revenue (ttm) 63.63B
Net Income (ttm) 8.03B
EPS (ttm) N/A
PE Ratio 7.78
Forward PE 7.85
Profit Margin 12.62%
Debt to Equity Ratio 0.66
Volume 73,079,300
Avg Vol 74,560,586
Day's Range N/A - N/A
Shares Out 5.69B
Stochastic %K 35%
Beta 0.54
Analysts Sell
Price Target $28.23

Company Profile

Pfizer Inc. discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular and migraine under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and tre...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 212 733 2323
Address:
66 Hudson Boulevard East, New York, United States
taxplanr
taxplanr Nov. 22 at 7:15 PM
Do you think she took the jab? $BNTX $MRNA $PFE https://www.cbsnews.com/news/jfk-granddaughter-tatiana-schlossberg-cancer/
0 · Reply
dagster01
dagster01 Nov. 22 at 6:01 PM
$VKTX $LLY $PFE Of course, a phase 2 study focuses on dosing levels in orser to determine what doses and potential titrations manximize efficacy and minimize AEs. That said, Viking will file an IND for their amylin formulary by EOY, putting them about two years behind Lilly's entrant. It almost looks like Viking is Lilly's Mini Me, gicen their GLP-1/GIP dual agonist and amylin formularies. Viking is also working on a calcitonin agonist that, with amylin, will yield another dual agonist, DACRA, that may be another game-changer. Eventually, all four might be balanced in a quad-agonist offering, though that's pretty far in the future.
1 · Reply
thrill__seeker
thrill__seeker Nov. 22 at 5:09 PM
$BYND Beyond IV has rebranded,a major catalyst, now recognized by the nations leading health organizations: American diabetes association, American heart association certified, good housekeeping s nutritionist approved emblem, and more on their website. Those names and emblems on the box like the heart man more sales, as the GLP-1 drugs have made people health conscious. Junk food and meat have had bad earnings since $NVO , $PFE and $LLY started seeking them. I'm also an MD. Now who's the village idiot.
2 · Reply
biolover
biolover Nov. 22 at 3:25 PM
$VKTX that is exaggerated form non escalation dose with high rate of fatigue , alopecia , vomit and DC. On top of slow heart rate. I detailed the data if you go to my previous posts. Wt loss in escalation dose was about 14% Alopecia is particularly concerning 10% even in $LLY slow escalation dose. Will be big issue for women ? Could screw up all $PFE Bourla team plan with Metsera combination and limit class use. Lilly should show alopecia grading ( was not detailed in Lancet paper )
1 · Reply
MrPeanutEsquire
MrPeanutEsquire Nov. 22 at 2:52 PM
$PFE Looks like we might be green all weekend! Thanks to the Jim Cramer endorsement no doubt
1 · Reply
Tiger65
Tiger65 Nov. 22 at 12:18 PM
$PFE Getting vaccinated has never been cool. But while in a democracy nobody can be forced to do so, Spock would still say that it is logical for statistical reasons to get a jab as a preventive measure on a yearly basis. What is true is that AI has made a lot of progress, especially in biotechnology (google for Spanish Flu Research).
1 · Reply
patricia101
patricia101 Nov. 22 at 12:11 PM
$PFE
0 · Reply
Blizzy
Blizzy Nov. 22 at 6:11 AM
$PFE fun fact - been loading the $30 Jan 28’ call options after getting burned on the 26’ call options (sold in May), might get burned on $30 Jan 27’ call options??? At this point $28 seems like a Herculean effort to reach
1 · Reply
TrevorCoryCapital
TrevorCoryCapital Nov. 22 at 5:57 AM
$PFE $NVO doing vaccines is still cool
0 · Reply
lihsus
lihsus Nov. 22 at 4:35 AM
$PFE I don’t normally like what Cramer says , but he’s on point on this one : To Cramer, Pfizer can act as a "bond equivalent," noting that the pharmaceutical giant has a nearly 6.9% yield. He also suggested that the drug maker has the potential to use the businesses it's acquired recently to build up a powerful pipeline — which could offset the numerous patent expirations the company is facing over the next few years. Cramer also said Pfizer's hefty cash flow allows it to easily cover the dividend, adding that longer term, the company could "get through this tricky period" and see its stock break out.
1 · Reply
Latest News on PFE
U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Nov 21, 2025, 1:24 PM EST - 1 day ago

U.S. FDA Approves PADCEV® plus Keytruda® for Certain Patients with Bladder Cancer

Pfizer Crosses Below Key Moving Average Level

Nov 20, 2025, 4:05 PM EST - 1 day ago

Pfizer Crosses Below Key Moving Average Level

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

Nov 20, 2025, 11:17 AM EST - 2 days ago

$100,000 In The S&P 500's 5 Cheapest Healthcare Stocks, 4% Average Dividend Yield

AMGN BMY GILD IVV MRK SPY VOO

October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs

Nov 19, 2025, 5:43 PM EST - 2 days ago

October Readers Identified 10 Ideal "Safer" Dividends In 39 Dogs

CAG CIM EPD HAFN HRL IPG KEY

Pfizer: Is This Pharma Giant Finally A Bargain

Nov 19, 2025, 3:51 PM EST - 2 days ago

Pfizer: Is This Pharma Giant Finally A Bargain

Pfizer in $41.5 million settlement with Texas over ADHD drug

Nov 19, 2025, 10:31 AM EST - 3 days ago

Pfizer in $41.5 million settlement with Texas over ADHD drug

Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript

Nov 19, 2025, 6:58 AM EST - 3 days ago

Pfizer Inc. (PFE) Presents at Jefferies London Healthcare Conference 2025 Transcript

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

Nov 18, 2025, 4:21 PM EST - 3 days ago

Why biotech and drug stocks are on the mend even though the rest of the market is hurting

AZN JNJ LLY MDT MRK NVO OLMA

Global drugmakers rush to boost US presence as tariff threat looms

Nov 18, 2025, 8:25 AM EST - 4 days ago

Global drugmakers rush to boost US presence as tariff threat looms

ABBV AMGN AZN BIIB GILD GSK JNJ

US-Saudi event to include CEOs from Chevron, Qualcomm, Pfizer, source says

Nov 17, 2025, 6:54 PM EST - 4 days ago

US-Saudi event to include CEOs from Chevron, Qualcomm, Pfizer, source says

CVX QCOM CSCO GD

3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List

Nov 17, 2025, 4:05 PM EST - 4 days ago

3 Best Healthcare Stocks: Quant Strong Buys From Goldman's 'Alpha' List

INCY PPH VRTX XBI XLV

Activist Starboard sells Pfizer stake after pushing for changes

Nov 14, 2025, 6:33 PM EST - 7 days ago

Activist Starboard sells Pfizer stake after pushing for changes

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

Nov 14, 2025, 3:19 PM EST - 7 days ago

Biopharma companies have confidence in their ability to do deals: BMO's Evan Seigerman

ABBV AZN JNJ LLY MRK NVO XLV

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

Nov 14, 2025, 7:02 AM EST - 8 days ago

Wall Street's Most Accurate Analysts Give Their Take On 3 Health Care Stocks Delivering High-Dividend Yields

VTRS XRAY

Pfizer's ex-R&D chief Dolsten withdraws from Novo Nordisk board race

Nov 13, 2025, 6:19 PM EST - 8 days ago

Pfizer's ex-R&D chief Dolsten withdraws from Novo Nordisk board race

NVO

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

Nov 13, 2025, 5:20 PM EST - 8 days ago

Pfizer sheds BioNTech stake years after blockbuster COVID vaccine tie-up

BNTX

Pfizer CEO: RFK Jr. "clearly" was not his HHS Secretary choice

Nov 13, 2025, 2:16 PM EST - 9 days ago

Pfizer CEO: RFK Jr. "clearly" was not his HHS Secretary choice

Pfizer CEO: AI will help with medicine's next big breakthrough

Nov 13, 2025, 1:07 PM EST - 9 days ago

Pfizer CEO: AI will help with medicine's next big breakthrough

Pfizer Completes Acquisition of Metsera

Nov 13, 2025, 11:26 AM EST - 9 days ago

Pfizer Completes Acquisition of Metsera

MTSR

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

Nov 13, 2025, 11:10 AM EST - 9 days ago

Pfizer Seeks To Exit BioNTech Investment After Lucrative Covid Vaccine Run

BNTX

Metsera shareholders vote for $10 billion acquisition by Pfizer

Nov 13, 2025, 9:18 AM EST - 9 days ago

Metsera shareholders vote for $10 billion acquisition by Pfizer

MTSR

BioNTech says collaboration with Pfizer remains unchanged

Nov 13, 2025, 8:17 AM EST - 9 days ago

BioNTech says collaboration with Pfizer remains unchanged

BNTX

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Nov 12, 2025, 10:00 AM EST - 10 days ago

Pfizer Invites Public to View and Listen to Webcast of Pfizer Discussion at Healthcare Conference

Johnson Fistel Investigates Fairness of Proposed Sale of Metsera

Nov 11, 2025, 1:57 PM EST - 11 days ago

Johnson Fistel Investigates Fairness of Proposed Sale of Metsera

Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript

Nov 11, 2025, 3:31 AM EST - 11 days ago

Pfizer Inc. (PFE) Discusses Clinical Development Strategy for 4404 Bispecific Antibody in Oncology Transcript

Pfizer to buy Metsera in deal worth up to $10 billion

Nov 10, 2025, 10:30 AM EST - 12 days ago

Pfizer to buy Metsera in deal worth up to $10 billion

MTSR

Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs

Nov 10, 2025, 10:21 AM EST - 12 days ago

Pfizer CEO: Metsera deal gives us 'one of the most exciting, advanced portfolios' in obesity drugs

MTSR

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Nov 10, 2025, 8:05 AM EST - 12 days ago

Pfizer won its fight to buy an obesity-drug maker. It took an extra $1.7 billion and a phone call.

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.

Nov 10, 2025, 7:32 AM EST - 12 days ago

Pfizer Is Buying Weight-Loss Drugmaker Metsera. Why Novo Nordisk Is the Winner.

MTSR NVO

Dividend Income: Lanny's September 2025 Summary

Nov 10, 2025, 5:27 AM EST - 12 days ago

Dividend Income: Lanny's September 2025 Summary

O PEP PM TGT VYM VZ

U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer

Nov 10, 2025, 3:45 AM EST - 12 days ago

U.S. Senate Makes Progress on Shutdown Deal, Novo Nordisk Loses Out to Pfizer

NVO

Pfizer wins $10 billion bidding war for obesity drug developer

Nov 8, 2025, 4:14 PM EST - 13 days ago

Pfizer wins $10 billion bidding war for obesity drug developer

Pfizer clinches $10 billion Metsera deal, outbidding Novo Nordisk

Nov 8, 2025, 9:54 AM EST - 14 days ago

Pfizer clinches $10 billion Metsera deal, outbidding Novo Nordisk

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

Nov 8, 2025, 6:38 AM EST - 14 days ago

Healthcare Q3 Dividend Roundup: I Prefer AbbVie Over Pfizer

ABBV

Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war

Nov 7, 2025, 10:07 PM EST - 14 days ago

Pfizer has agreed to buy weight-loss drug startup Metsera in a deal that could be worth more than $10 billion, besting rival Novo Nordisk following a heated bidding war

MTSR

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

Nov 7, 2025, 9:32 PM EST - 14 days ago

Pfizer and Metsera Enter into Merger Agreement Amendment; Metsera's Board of Directors Reaffirms Support of Merger with Pfizer

MTSR

Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports

Nov 7, 2025, 7:59 PM EST - 14 days ago

Pfizer sweetens offer for Metsera in bidding war against Novo, Bloomberg News reports

MTSR

Pfizer: The Storm Has Passed -- Tailwinds Ahead

Nov 6, 2025, 2:00 PM EST - 16 days ago

Pfizer: The Storm Has Passed -- Tailwinds Ahead

What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?

Nov 6, 2025, 12:01 PM EST - 16 days ago

What is Metsera, the target in Pfizer's and Novo Nordisk's bidding war?

MTSR NVO

Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal

Nov 6, 2025, 11:40 AM EST - 16 days ago

Pfizer To Raise Metsera Bid After Court Denies Attempt To Block Rival Deal

MTSR

Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle

Nov 6, 2025, 8:49 AM EST - 16 days ago

Metsera weighs rival bids from Pfizer, Novo in $10 billion obesity drug battle

MTSR

Pfizer's Slow Burn Comeback

Nov 6, 2025, 7:20 AM EST - 16 days ago

Pfizer's Slow Burn Comeback

Wall Street Breakfast Podcast: Government Shutdown Hits New Altitude

Nov 6, 2025, 6:29 AM EST - 16 days ago

Wall Street Breakfast Podcast: Government Shutdown Hits New Altitude

MTSR NVO WBD

Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman

Nov 5, 2025, 6:02 PM EST - 16 days ago

Expect Pfizer bid to beat Novo for Metsera, says BMO's Evan David Seigerman

MTSR

Pfizer Responds to Delaware Chancery Court Ruling

Nov 5, 2025, 5:08 PM EST - 16 days ago

Pfizer Responds to Delaware Chancery Court Ruling

Pfizer preparing to raise its bid for Metsera, WSJ reports

Nov 5, 2025, 5:02 PM EST - 16 days ago

Pfizer preparing to raise its bid for Metsera, WSJ reports

MTSR

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk

Nov 5, 2025, 4:52 PM EST - 16 days ago

Pfizer is preparing to sweeten its offer again for Metsera, the weight-loss drug startup at the center of a bidding war that also involves Novo Nordisk

MTSR NVO

Delaware judge says she will not block Metsera from ending Pfizer deal

Nov 5, 2025, 4:20 PM EST - 16 days ago

Delaware judge says she will not block Metsera from ending Pfizer deal

MTSR

Pfizer says it removed some conditions from its Metsera bid

Nov 5, 2025, 2:19 PM EST - 17 days ago

Pfizer says it removed some conditions from its Metsera bid

MTSR

Pfizer: Market Still Pricing It At Crisis Valuations

Nov 5, 2025, 11:30 AM EST - 17 days ago

Pfizer: Market Still Pricing It At Crisis Valuations

taxplanr
taxplanr Nov. 22 at 7:15 PM
Do you think she took the jab? $BNTX $MRNA $PFE https://www.cbsnews.com/news/jfk-granddaughter-tatiana-schlossberg-cancer/
0 · Reply
dagster01
dagster01 Nov. 22 at 6:01 PM
$VKTX $LLY $PFE Of course, a phase 2 study focuses on dosing levels in orser to determine what doses and potential titrations manximize efficacy and minimize AEs. That said, Viking will file an IND for their amylin formulary by EOY, putting them about two years behind Lilly's entrant. It almost looks like Viking is Lilly's Mini Me, gicen their GLP-1/GIP dual agonist and amylin formularies. Viking is also working on a calcitonin agonist that, with amylin, will yield another dual agonist, DACRA, that may be another game-changer. Eventually, all four might be balanced in a quad-agonist offering, though that's pretty far in the future.
1 · Reply
thrill__seeker
thrill__seeker Nov. 22 at 5:09 PM
$BYND Beyond IV has rebranded,a major catalyst, now recognized by the nations leading health organizations: American diabetes association, American heart association certified, good housekeeping s nutritionist approved emblem, and more on their website. Those names and emblems on the box like the heart man more sales, as the GLP-1 drugs have made people health conscious. Junk food and meat have had bad earnings since $NVO , $PFE and $LLY started seeking them. I'm also an MD. Now who's the village idiot.
2 · Reply
biolover
biolover Nov. 22 at 3:25 PM
$VKTX that is exaggerated form non escalation dose with high rate of fatigue , alopecia , vomit and DC. On top of slow heart rate. I detailed the data if you go to my previous posts. Wt loss in escalation dose was about 14% Alopecia is particularly concerning 10% even in $LLY slow escalation dose. Will be big issue for women ? Could screw up all $PFE Bourla team plan with Metsera combination and limit class use. Lilly should show alopecia grading ( was not detailed in Lancet paper )
1 · Reply
MrPeanutEsquire
MrPeanutEsquire Nov. 22 at 2:52 PM
$PFE Looks like we might be green all weekend! Thanks to the Jim Cramer endorsement no doubt
1 · Reply
Tiger65
Tiger65 Nov. 22 at 12:18 PM
$PFE Getting vaccinated has never been cool. But while in a democracy nobody can be forced to do so, Spock would still say that it is logical for statistical reasons to get a jab as a preventive measure on a yearly basis. What is true is that AI has made a lot of progress, especially in biotechnology (google for Spanish Flu Research).
1 · Reply
patricia101
patricia101 Nov. 22 at 12:11 PM
$PFE
0 · Reply
Blizzy
Blizzy Nov. 22 at 6:11 AM
$PFE fun fact - been loading the $30 Jan 28’ call options after getting burned on the 26’ call options (sold in May), might get burned on $30 Jan 27’ call options??? At this point $28 seems like a Herculean effort to reach
1 · Reply
TrevorCoryCapital
TrevorCoryCapital Nov. 22 at 5:57 AM
$PFE $NVO doing vaccines is still cool
0 · Reply
lihsus
lihsus Nov. 22 at 4:35 AM
$PFE I don’t normally like what Cramer says , but he’s on point on this one : To Cramer, Pfizer can act as a "bond equivalent," noting that the pharmaceutical giant has a nearly 6.9% yield. He also suggested that the drug maker has the potential to use the businesses it's acquired recently to build up a powerful pipeline — which could offset the numerous patent expirations the company is facing over the next few years. Cramer also said Pfizer's hefty cash flow allows it to easily cover the dividend, adding that longer term, the company could "get through this tricky period" and see its stock break out.
1 · Reply
Kornie7
Kornie7 Nov. 22 at 4:14 AM
$PFE In hindsight, while growth AI ticker 40-50% drop we could have hide in here LOL
2 · Reply
MoneyGroupLLC
MoneyGroupLLC Nov. 22 at 3:46 AM
Enter: $PFE Calls Strike Price: $26 Expiry Date: DEC 12 2025 Buy in Price: $0.40 - $0.40 Sell Price: $0.80 Profit : +101% (Turn every $1 into $2.01) Want Profitable Real-Time Options Alerts? 👉 https://moneygroup.us
0 · Reply
LiquidThetaOptions
LiquidThetaOptions Nov. 22 at 2:41 AM
💎 LiquidTheta® Live Actionable Trade Asset: $PFE Contracts: $PFE December 18, 2026 $25 Calls Scale in: $2.29- $2.80 Scale out: $8.91-$15.27 Profit Potential : 156% ROI Blended Join 💎 Here: https://liquidtheta.com
0 · Reply
BullishPullBacks
BullishPullBacks Nov. 22 at 1:16 AM
$PFE Got in, think health stocks will be doing well
1 · Reply
JoeTheMiner
JoeTheMiner Nov. 22 at 12:32 AM
$GUTS imagine having same watchers as $ABCL or $PFE
1 · Reply
xtremdelt8
xtremdelt8 Nov. 21 at 11:47 PM
$ENB $O $PFE Cramer just did a segment praising in these. R.I.P.
1 · Reply
PFElinepfrenzy1990
PFElinepfrenzy1990 Nov. 21 at 11:41 PM
$PFE - The year is 2349. Pfizer is celebrating their 500th anniversary. The CEO and Chairman is Albert Bourla, after he was cryopreserved in 2054 and resurrected in 2321. Pfizer’s market cap is, finally, 1T! Yay! Nvidia’s valuation is 30E. Lilly’s, 14E. Life is good.
1 · Reply
MrPeanutEsquire
MrPeanutEsquire Nov. 21 at 11:39 PM
$PFE Tonight Cramer likes our pipeline and thinks we could be near a breakout. Just in case anyone had any doubts
2 · Reply
sister
sister Nov. 21 at 11:17 PM
$PFE can always get cheaper . . . $MRNA too
0 · Reply
lihsus
lihsus Nov. 21 at 11:11 PM
$PFE a $60 stock currently on deep discount. Buy now .
0 · Reply
HedgeAlerts
HedgeAlerts Nov. 21 at 10:35 PM
Hedge Alert Live - Protect Your Portfolio Contract: $PFE $25.00 Put · NOV 28, 2025 Exp Entry Price: $0.29 - $0.30 Exit Price Target: $0.67 Profit Margin: +131% Hold Period: 1-3 days MAX ONLY USE THESE ALERTS ON RED/DOWN MARKET DAYS. Monetize Red Market Days: https://hedgealerts.com
0 · Reply
Broview
Broview Nov. 21 at 10:33 PM
$PFE dividend sustainable?
3 · Reply